Marrow Stromal Cells for Interleukin-2 Delivery in Cancer Immunotherapy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Marrow stromal cells (MSCs) can be easily gene-modified and clonally expanded making them ideal candidates for transgenic cell therapy. However, recent reports suggest that MSCs possess immunosuppressive effects, which may limit their clinical applications. We investigated whether interleukin (IL)-2 gene-modified MSCs can be used to mount an effective immune response against the poorly immunogenic B16 melanoma model. We first show that primary MSCs mixed with B16 cells and injected subcutaneously in syngeneic recipients do not affect tumor growth. On the other hand, IL-2-producing MSCs mixed with B16 cells significantly delayed tumor growth in an IL-2 dose-dependent manner. Furthermore, we observed that matrix-embedded IL-2-producing MSCs injected in the vicinity of preestablished B16 tumors led to absence of tumor growth in 90% of treated mice (p < 0.001). We demonstrated that tumor-bearing mice treated with IL-2-producing MSCs developed CD8-mediated tumor-specific immunity and significantly delayed tumor growth of a B16 cell challenge (p < 0.05). In addition, treatment of cd8-/-, cd4-/- and beige mice revealed that CD8+ and natural killer (NK) cells, but not CD4+ cells, were required to achieve antitumor effect. In conclusion, MSCs can be exploited to deliver IL-2 and generate effective immune responses against melanoma in mice with normal immune systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 5×
“Furthermore, mouse MSCs were reported to favor tumor growth of B16 melanoma cells in allogeneic mice (Djouad et al., 2003) possibly because MSCs express receptors for several tumor stroma-derived growth factors.”
Influential
Cited by
Bio-inspired, bioengineered and biomimetic drug delivery carriers
Yoo, J.-W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3499 · Cited by 1,236
Stem Cell Paracrine Actions and Tissue Regeneration
Baraniak, P. R., & McDevitt, T. C. (2010) · Regenerative Medicine · doi:10.2217/rme.09.74 · Cited by 843
Sotiropoulou, P. A., Perez, S. A., Salagianni, M., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0331 · Cited by 627
Eliopoulos, N., Stagg, J., Lejeune, L., Pommey, S., & Galipeau, J. (2005) · Blood · doi:10.1182/blood-2005-03-1004 · Cited by 558
Self-citationKievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Metadata
- Authors
- Stagg, J., Lejeune, L., Paquin, A., & Galipeau, J.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2004-06
- Volume
- 15
- Issue
- 6
- Pages
- 597-608
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2015853802
- Cited by
- 109
- References
- 2
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Marrow Stromal Cells for Interleukin-2 Delivery in Cancer Immunotherapy. https://app.cochat.ai/papers/10.1089/104303404323142042
- The paper
- Stagg, J., Lejeune, L., Paquin, A., & Galipeau, J. (2004). Marrow Stromal Cells for Interleukin-2 Delivery in Cancer Immunotherapy. Human Gene Therapy. https://doi.org/10.1089/104303404323142042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.